CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Novozymes [NZYM- B]

Lone Dybdal Nilsson, VP of Applied Research in Agriculture and Industrial Bioprocessing

Biotechnology should have Preferred Regulatory Pathways to Catalyze the Bioscience Revolution

Lone Dybdal Nilsson

Lone Dybdal Nilsson

U.S. regulations must be updated to fully leverage biotechnologies for a better world.


Using the tools of nature to unleash the power of nature is a strong path for providing biological answers for better lives in a growing world and to address the sustainability challenges we are facing. Nevertheless, greater regulatory certainty for new biologic products for farming is needed to bring biosolutions to bear.


In nature, microorganisms mutate and exchange genetic information continuously, to adapt to the challenges they face while surviving in their changing environments. Such continuous adaptation can serve to improve capabilities like utilization of new sources of nutrition, or ability to overcome threats from other microorganisms.


With modern sequencing technology microbial genomes and any small alteration can be mapped with extreme accuracy, and this enables highly specific alteration of microbial genomes. In the past decades, methods for specific and controlled modification of genetic information in microorganisms have been employed with an increasing focus on their role in unlocking sustainability using bioscience solutions.


For example, CRISPR-Cas techniques for gene editing have been implemented in many laboratories around the world. These are tools that microorganisms do also apply in nature, but in some regulatory schemes they are subject to extreme scrutiny in an approval process that is not clear or aligned between agencies. This is done to a degree that is limiting access to the benefits of transformative climate-smart solutions for farmers and consumers.


Gene editing tools are highly effective for removing genes that could lead to expression of harmful metabolites or incur inappropriate resistance in an organism (like e.g., antibiotic resistance genes). They are also useful for enhancing a microorganism’s expression of compounds that it already expresses to grow and defend itself in nature (e.g., enzymes), or adding beneficial capabilities from other microorganisms, leading to higher efficacy in the application.


With such techniques, controlled modification of microorganisms can be used to strengthen the beneficial impact of biological solutions. This includes addressing societal needs like breaking down waste material (for recycling and less landfill) or strengthening the gut health of a chicken or the nutrition uptake of a corn plant (to increase production yield and reduce the use of antibiotics and chemical pesticides in the food chain). In other words, it is possible to accelerate an otherwise slow genetic evolution of microorganisms, for the benefit of human health, and for the benefit of our planet.


With modern sequencing technology microbial genomes and any small alteration can be mapped with extreme accuracy, and this enables highly specific alteration of microbial genomes.


Our world needs all the help it can get. We strongly support efforts to update the regulatory framework for genetically modified microorganisms across all sectors. Regulatory uncertainty stymies industry innovation. But the reverse–a nimble, fact-based approach– enables the government to be a full and agile partner able to take advantage of emergent, beneficial and safe biotechnological solutions to address global challenges.


Only with a progressive and science-based regulatory framework and a framework that is consistent between the main agencies with authority on agriculture (USDA, FDA, EPA) can the U.S. fully deploy the opportunities of biotechnology.


Let’s demystify genetic evolution and make the world a better place. Sustainably.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/biotechnology-should-have-preferred-regulatory-pathways-to-catalyze-the-bioscience-revolution-nwid-1199.html